title: The effect of cromolyn sodium and albuterol on early and late phase bronchoconstriction and airway leukocyte infiltration after allergen challenge of nonanesthetized guinea pigs.
abstract: We describe the effects of the antiallergic drug cromolyn sodium and the beta 2-selective adrenoceptor agonist albuterol against early and late phase changes in specific airways conductance (sGaw) and leukocyte infiltration into the airways after allergen challenge of nonanesthetized guinea pigs. Inhalation of ovalbumin by sensitized guinea pigs induced three phases of airways obstruction: an early asthmatic response (EAR) peaking at 2 h, a late response (LAR) peaking at 17 h, and a further late response (LLAR) being observed at 72 h. The LAR was accompanied by a 13-fold rise in neutrophils and a four-fold rise in eosinophils recovered by bronchoalveolar lavage (BAL) at 17 h. By 72 h, the BAL content of neutrophils had returned to near normal, whereas eosinophil numbers had risen to 6.7-fold above baseline. Inhalation of an aerosolized solution of cromolyn, 10 mg/ml, 15 min before challenge inhibited both the EAR and LAR and the influx of neutrophils into the airways at 17 h but had no effect on eosinophil accumulation. Inhalation of cromolyn at 6 h, i.e., after the completion of the EAR, inhibited the LAR, the LLAR, and the rise in eosinophils at 72 h but did not reduce the influx of neutrophils at 17 h. Administration of cromolyn at both 15 min before and 6 h after challenge inhibited all changes in sGaw and reduced the accumulation of neutrophils at 17 h and the influx of eosinophils at 72 h. In contrast, inhalation of albuterol, 0.1 mg/ml, 15 min before allergen provocation blocked the EAR and the rise in BAL neutrophils at 17 h but did not inhibit the LAR. Inhalation of albuterol at 6 h partially reversed the LAR but had no effect on either the LLAR or cellular changes. Given at both times, albuterol inhibited the EAR and neutrophil accumulation at 17 h and partially reversed the LAR but produced no other effects.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Immunopharmacology Group, Southampton General Hospital, United Kingdom.
authors.forename: P A
authors.initials: PA
authors.lastname: Hutson
authors.forename: S T
authors.initials: ST
authors.lastname: Holgate
authors.forename: M K
authors.initials: MK
authors.lastname: Church
mesh_terms: D000402:Airway Obstruction / Q000503:physiopathology; D000403:Airway Resistance / Q000187:drug effects; D000420:Albuterol / Q000494:pharmacology*; D000485:Allergens / Q000276:immunology; D000818:Animals; D001249:Asthma / Q000276:immunology / Q000503:physiopathology*; D001980:Bronchi / Q000187:drug effects* / Q000503:physiopathology; D001992:Bronchoalveolar Lavage Fluid / Q000473:pathology; D004205:Cromolyn Sodium / Q000494:pharmacology*; D006168:Guinea Pigs; D007962:Leukocytes / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology*; D008297:Male; D010047:Ovalbumin / Q000276:immunology; D013997:Time Factors
chemical_list: D000485:Allergens; D010047:Ovalbumin; D004205:Cromolyn Sodium; D000420:Albuterol